A current Phase 2 study is ongoing to evaluate the efficacy and safety of monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pNET, VHL disease-associated tumors, advanced gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with HIF-2α-related genetic alterations (86). The gene discussed is EPAS1; the disease is hereditary pheochromocytoma-paraganglioma.